🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Daniel Moore Palhares, Hany, arjun sahgal, Sunnybrook Health Sciences Centre et al discuss temporal ADC changes during chemoradiation: An imaging biomarker for tumor response monitoring and spatial recurrence prediction in glioblastoma. Read about it in the #RedJournal: tinyurl.com/redsnbrk

📢data from SHERBET metà analysis: SBRT has excellent long-term efficacy with significantly decreased BCF compared to HDR-BT. #ESTRO25 ,ESTRO ,Dr. Andrew Loblaw

Surprising data from Sunnybrook Dr. Andrew Loblaw for higher BCR with HDR mono vs sbrt - controversy enough to crash the slides.

🔥⚡️🚀 First prospective comparison of SBRT vs HDR-BT in prostate cancer (SHERBET study): SBRT shows superior long-term efficacy & lower BCF. Two-fraction HDR-BT w/o ADT? Only in trials for intermediate-risk pts. Great work from Sunnybrook team! #RadOnc #GU25 Dr. Andrew Loblaw

Active Surveillance for Favorable intermediate risk prostate cancer. Safe option for select patients. Data presented on #ESTRO25 Dr. Andrew Loblaw Danny Vesprini

🚀 New in Journal of Clinical Oncology - ROBOMET shorturl.at/NawNo! SABR vs standard #radiotherapy for painful bone mets. ✅ Pain relief at 1 month: 🔹 SABR (20 Gy single dose): 37% complete response 🔸 versus (8 Gy): 25% complete response ⚡ at 3-months ⬆️ withSABR: 54% vs 31%, p= .048

1/3 Was lucky to present our ASTuTE trial interim results #ESTRO25 in Vienna Q: How does the @ArteraAI prostate test influence shared ST-ADT decision making - 200 patients, across 28 Australian centers (GenesisCare) - 150 UIR and 50 FIR prostate cancer - Only 15% biomarker +ve

Fantastic Grey Zone topic for June of 2025 Which Way to (INDI)GO? Case: 42 yo male with STR of a WHO grade 2 IDH mutant (IDH1 R132H) astrocytoma with loss of ATRX, no 1p/19q codeletion, and no homozygous deletion of CDKN2A/B. redjournal.org/article/S0360-… IJROBP - The Red Journal

Thank you to IJROBP - The Red Journal for giving Stanislav (Stas) Lazarev, MD and I the opportunity to contribute to the most recent Gray Zone case “The INDIGO Illusion: The Evidence Still Supports Chemoradiation Therapy in Patients with Low-Grade Glioma” redjournal.org/article/S0360-…

🔬 AVATAR trial published(ER+/HER2– MBC on AI + CDK4/6i): In OPD, SABR delayed therapy change (mPFS 9.9 mo) 🔷 44% on same Rx at 12 mo 🔷 36% at 24 mo Some received SABR 2–3× for new oligoprogressions—modified endpoints may better reflect its value. ascopubs.org/doi/10.1200/OA…

🧠💥 Pre-op SRS for brain mets is gaining traction. But must we resect 1–3 days after? 🤔 We ran a small feasibility trial. Biological rationale: keeping the irradiated tumor in situ longer may allow immune responses within the tumor to develop🕒 link.springer.com/article/10.100…

- 15 pts - Median SRS-to-surgery: 8 days - No earlier surgery for growth / oedema - No Grade >2 AEs - No issues with histopath diagnosis - Interestingly, the only BrM failure at 13.8m f/u had a 0-day SRS-to-surgery interval - Lab analyses to follow! Peter Mac Radiation Oncology

Rubén Del Castillo does it again! RSNA Resident and Fellow Roentgen Research Award for his work identifying favourable intermediate patients where #ActiveSurveillance is safe. N=1699, mFU 10.3y 🟰 freedom from Mets for men with GG1 or GG2 with APP4 <5% Radiation Oncology arjun sahgal Laura Dawson

C. Jillian Tsai, MD, PhD Sushil Shankar Siva Also take note of the new phase 3 pharma destiny trial - primary endpoint is TNTT…clinicaltrials.gov/study/NCT05950… so pharma are interested in measures like this

First study I’m aware of that integrates PSMA & MRI to define DIL and then treats DIL, prostate and pelvis all in 5 SBRT treatments. Should we have called it Super-FLAME?

Also brachy vs EBRT, n=710, phase 3 international RCT CCTG PR24

👏🏽👏🏽👏🏽 agree! it’s time to retire the “toxicity” moniker #radonc. We are stuck in the past!!!! Sue Yom Neha Vapiwala

Thrilled to complete my first year of fellowship! 🙌 Immense gratitude to all my mentors, especially Dr. Andrew Loblaw for shaping me into a better RadOnc. Honored to meet future RadOnc stars! 🌟